You are here

drug pricing

Azar's Plan To Tie U.S. Drug Prices To Foreign Ones Will Impact Investments In R&D

Azar's Plan To Tie U.S. Drug Prices To Foreign Ones Will Impact Investments In R&D

Forbes

Flag link:

Pharma CEOs didn’t show up for a congressional scolding, so progressives shadowboxed instead

Pharma CEOs didn’t show up for a congressional scolding, so progressives shadowboxed instead

Stat

pharma executives

Flag link:

What Bluebird Bio Gets Wrong In Pricing For Its $1.8 Million Drug

What Bluebird Bio Gets Wrong In Pricing For Its $1.8 Million Drug

Forbes

beta thalassemia

Flag link:

bluebird offers installment payments for Zynteglo gene therapy

bluebird offers installment payments for Zynteglo gene therapy

Pharmaforum

outcome-based pricing

beta thalassemia

Flag link:

Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?

Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?

Motley Fool

beta thalassemia

Flag link:

Bluebird sets $1.8M price tag for blood-disease gene therapy

Bluebird sets $1.8M price tag for blood-disease gene therapy

Biopharma Dive

beta thalassemia

Flag link:

The top 10 most-expensive meds in the U.S.—and they're not the usual suspects

The top 10 most-expensive meds in the U.S.—and they're not the usual suspects

Fierce Pharma

Spark Therapeutics

Flag link:

Move Over, Martin Shkreli: This Pharma Exec Is Accused Of Fixing Prices On 107 Drugs

Move Over, Martin Shkreli: This Pharma Exec Is Accused Of Fixing Prices On 107 Drugs

Forbes

Maureen Cavanaugh

Teva Pharmaceutical

price collusion

Flag link:

House progressives challenge drugmakers to come back to Capitol Hill

House progressives challenge drugmakers to come back to Capitol Hill

Stat

Gilead Sciences

Flag link:

How pharma could benefit from one of Congress’ signature drug pricing ideas

How pharma could benefit from one of Congress’ signature drug pricing ideas

Stat

Flag link:

From BIO meeting, Merck CEO Ken Frazier defends capitalism, drug industry

From BIO meeting, Merck CEO Ken Frazier defends capitalism, drug industry

Biopharma Dive

Flag link:

Cheaper Versions of the Most Expensive Drugs May be Coming, but Monopolies Will Likely Remain

Cheaper Versions of the Most Expensive Drugs May be Coming, but Monopolies Will Likely Remain

Motley Fool

Flag link:

Here's Why Generic-Drug Manufacturers Lost As Much As 43.2% in May

Here's Why Generic-Drug Manufacturers Lost As Much As 43.2% in May

Motley Fool

Flag link:

Greenwood : In Drug Pricing Debate, Politicians and Patients Are Not Talking About Same Price

Greenwood : In Drug Pricing Debate, Politicians and Patients Are Not Talking About Same Price

BIOTechNow

Flag link:

Patients, payers await pricing plans for bluebird's first approved gene therapy

Patients, payers await pricing plans for bluebird's first approved gene therapy

BioCentury

beta thalassemia

Flag link:

Is $2.1 million too much for a drug? For affected parents, there is no debate

Is $2.1 million too much for a drug? For affected parents, there is no debate

Stat

Flag link:

Why Concerns About a “Break Down” in Drug Pricing Are Misplaced

Why Concerns About a “Break Down” in Drug Pricing Are Misplaced

BIOTechNow

Flag link:

Is CEO pay linked to drug prices? Curious investors failed their campaign to find out

Is CEO pay linked to drug prices? Curious investors failed their campaign to find out

Fierce Pharma

Flag link:

On the pulse of ASCO: pricing and clinical trial access

On the pulse of ASCO: pricing and clinical trial access

Pharmaforum

clinical trial access

clinical trials

Flag link:

Maryland creates drug affordability review board

Maryland creates drug affordability review board

BioCentury

drug affordability review board

Flag link:

Pages